Trump 100% tariffs on drugs, 20% cut for US production
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump administration announced a 100% tariff on imported brand‑name drugs, with exemptions for companies that have secured U.S. manufacturing deals.
- Trump administration exempted large drugmakers that have struck agreements to build U.S. facilities and lower medication prices from the 100% tariff.
- Trump administration offered a reduced 20% tariff to drugmakers that pledge to bring production to the U.S. for the remainder of Trump's term.
- Trump administration is negotiating new drug‑pricing deals with smaller pharmaceutical companies, extending the voluntary‑agreement strategy used with larger firms.
- Trump administration frames the tariffs as a way to bring manufacturing back to the U.S. and make medicine prices more affordable ahead of the midterm elections.
Why it matters: Domestic manufacturers gain a competitive edge as foreign‑sourced drugs face a 100% tariff, while firms without U.S. production deals risk higher costs; the 20% reduced rate for pledges before the term’s end creates a clear incentive to shift manufacturing to the United States.
